Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding
Main Authors: | Volokhina, Elena, Westra, Dineke, Xue, Xiaoguang, Gros, Piet, van de Kar, Nicole, van den Heuvel, Lambert |
---|---|
Format: | Online |
Language: | English |
Published: |
Springer-Verlag
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407361/ |
Similar Items
-
Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
by: Wong, Edwin K.S., et al.
Published: (2013) -
Erratum to: aHUS caused by complement dysregulation: new therapies on the horizon
by: Waters, Aoife M., et al.
Published: (2012) -
Remission of aHUS neurological damage with eculizumab
by: Ávila, Ana, et al.
Published: (2015) -
A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
by: Rathbone, John, et al.
Published: (2013) -
Can eculizumab be discontinued in aHUS?: Case report and review of the literature
by: Sahutoglu, Tuncay, et al.
Published: (2016)